Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1982 Oct;79(19):6003-7.
doi: 10.1073/pnas.79.19.6003.

Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment

Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment

C Charriaut et al. Proc Natl Acad Sci U S A. 1982 Oct.

Abstract

Purified human native third component of complement, C3, was found to inhibit in vitro natural killer (NK) cell cytotoxicity in both mouse and human systems. The effect was dose and time dependent, a 50% inhibition being reached with 190 nM C3 (35 micrograms/ml) added during the NK assay or after a 30-min preincubation of the effector cells with this C3 concentration. C3 was shown to act at the effector-cell population level because pretreatment of the target cells did not modify the NK lysis. The inhibition was not due to general cytotoxicity nor to cell agglutination. Moreover, another in vitro cytotoxicity system (represented by alloreactive cytotoxic lymphocytes) was not affected by purified C3. Structural analysis of the active part of the C3 molecule shows that the C3-induced inhibition is supported by the C3a fragment. Release of carboxyl-terminal arginine residue by carboxypeptidase B, converting C3a into des-Arg77-C3a, did not alter the inhibitory effect displayed by this fragment. These results suggest that C3a may play an important role in the regulation of NK activity.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Immunol Methods. 1980;36(3-4):285-91 - PubMed
    1. Immunol Rev. 1979;44:165-208 - PubMed
    1. J Immunol. 1981 Jun;126(6):2321-7 - PubMed
    1. J Exp Med. 1981 Jun 1;153(6):1615-28 - PubMed
    1. FEBS Lett. 1981 Dec 21;136(1):111-4 - PubMed

Publication types

LinkOut - more resources